Morgan Stanley
ATXI

Morgan Stanley’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Morgan Stanley’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$195 – 7927
2023
Q3 		$195 Sell
4
-2
-33% -$141 ﹤0.01% 7389
2023
Q2 		$484 Hold
6
– – ﹤0.01% 7379
2023
Q1 		$482 Sell
6
-38
-86% -$3.51K ﹤0.01% 7442
2022
Q4 		$3.87K Buy
44
+24
+120% +$4.35K ﹤0.01% 7218
2022
Q3 		$15K Buy
+20
New +$6.4K ﹤0.01% 6932
2022
Q2 		– Sell
-1
Closed – – 8029
2022
Q1 		$0 Buy
+1
New +$747 ﹤0.01% 8161
2021
Q4 		– Hold
0
– – – 8142
2021
Q3 		– Hold
0
– – – 8051
2021
Q2 		– Hold
0
– – – 7823
2021
Q1 		– Sell
-22
Closed -$151K – 7588
2020
Q4 		$149K Buy
22
+2
+10% +$10.5K ﹤0.01% 5738
2020
Q3 		$246K Buy
20
+15
+300% +$182K ﹤0.01% 5002
2020
Q2 		$66K Buy
5
+1
+25% +$11.3K ﹤0.01% 5576
2020
Q1 		$42K Buy
4
+1
+33% +$10K ﹤0.01% 5536
2019
Q4 		$31K Buy
3
+2
+200% +$14K ﹤0.01% 5991
2019
Q3 		$7K Buy
+1
New +$6.81K ﹤0.01% 6305
2018
Q2 		– Hold
0
– – – 6770
2018
Q1 		– Hold
0
– – – 6718
2017
Q4 		– Sell
-1
Closed -$5.1K – 6672
2017
Q3 		$4K Buy
+1
New +$7.34K ﹤0.01% 6332

Other funds holding ATXI

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley's ATXI Position: Q4 2023 in Review

Morgan Stanley sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2023, closing a stake of 4 shares — an estimated $195 sold.

Morgan Stanley first reported a position in ATXI in Q3 2017 and held it in 13 quarters. The position peaked at $246K in Q3 2020. 14 funds tracked by Wall St. Rank hold ATXI as of Q4 2023.

  • Morgan Stanley reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Morgan Stanley sold 4 Avenue Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $195.
  • Morgan Stanley first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2017 and held it in 13 quarters.
  • Morgan Stanley's Avenue Therapeutics, Inc. Common Stock position peaked at $246K in Q3 2020.
  • 14 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.